Palvella Therapeutics, Inc. Sales Revenue, Goods, Net (Deprecated 2018-01-31)
Palvella Therapeutics, Inc. (PVLA) reported Sales Revenue, Goods, Net (Deprecated 2018-01-31) of $0 for the 9-month period ending 2017-09-30, per its 10-Q filed 2017-11-13.
Discontinued › Expense Statement › Operating Expenses
us-gaap:SalesRevenueGoodsNet · last filed 2017-11-13
- Palvella Therapeutics, Inc. sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2017-09-30 was $0.00.
- Palvella Therapeutics, Inc. sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2017-06-30 was $0.00.
- Palvella Therapeutics, Inc. sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2017-03-31 was $0.00.
- Palvella Therapeutics, Inc. sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2016-12-31 was $0.00.
- Palvella Therapeutics, Inc. sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2016 was $0.00.
- Palvella Therapeutics, Inc. sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2015 was $0.00.
| Period end | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 3 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 6 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 9 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 12 month |
|---|---|---|---|---|
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-13 | $0.00 derived: sum of 2 quarters · filed 2017-11-13 | $0.00 10-Q · filed 2017-11-13 | $0.00 derived: sum of 4 quarters · filed 2017-11-13 |
| 2017-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-11 | $0.00 10-Q · filed 2017-08-11 | $0.00 derived: sum of 3 quarters · filed 2017-08-11 | $0.00 derived: sum of 4 quarters · filed 2017-08-11 |
| 2017-03-31 | $0.00 10-Q · filed 2017-05-15 | $0.00 derived: sum of 2 quarters · filed 2017-05-15 | $0.00 derived: sum of 3 quarters · filed 2017-05-15 | $0.00 derived: sum of 4 quarters · filed 2017-05-15 |
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-30 | $0.00 derived: sum of 2 quarters · filed 2017-03-30 | $0.00 derived: sum of 3 quarters · filed 2017-03-30 | $0.00 10-K · filed 2017-03-30 |
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-10 | $0.00 derived: sum of 2 quarters · filed 2016-11-10 | $0.00 10-Q · filed 2016-11-10 | $0.00 derived: sum of 4 quarters · filed 2016-11-10 |
| 2016-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-11 | $0.00 10-Q · filed 2016-08-11 | $0.00 derived: sum of 3 quarters · filed 2016-08-11 | $0.00 derived: sum of 4 quarters · filed 2016-08-11 |
| 2016-03-31 | $0.00 10-Q · filed 2016-05-12 | $0.00 derived: sum of 2 quarters · filed 2016-05-12 | $0.00 derived: sum of 3 quarters · filed 2016-05-12 | $0.00 derived: sum of 4 quarters · filed 2016-05-12 |
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-23 | $0.00 derived: sum of 2 quarters · filed 2016-03-23 | $0.00 derived: sum of 3 quarters · filed 2016-03-23 | $0.00 10-K · filed 2016-03-23 |
| 2015-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-13 | $0.00 derived: sum of 2 quarters · filed 2015-11-13 | $0.00 10-Q · filed 2015-11-13 | |
| 2015-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-13 | $0.00 10-Q · filed 2015-08-13 | ||
| 2015-03-31 | $0.00 10-Q · filed 2015-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |